A rare adverse effect of montelukast treatment: Ecchymosis

Respiratory Care

Volumn 58, Issue 9, 2013, Pages

  Aypak, Cenk ^a   Türedi, Özlem ^a   Solmaz, Nisa ^a   Yikilkan, Hülya ^a   Görpelioǧlu, Süleyman ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adverse effects; Bruising; Leukotriene antagonists; Montelukast

Indexed keywords

BUDESONIDE; HEMOGLOBIN; IMMUNOGLOBULIN E; MONTELUKAST;

ADULT; ALLERGIC RHINITIS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG WITHDRAWAL; ECCHYMOSIS; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HISTOLOGY; HUMAN; HUMAN TISSUE; LEG; LEUKOCYTE COUNT; MEDICAL HISTORY; MODERATE PERSISTENT ASTHMA; PARANASAL SINUS; PHYSICAL EXAMINATION; SKIN BRUISING; THROMBOCYTE COUNT;

ADVERSE EFFECTS; BRUISING; LEUKOTRIENE ANTAGONISTS; MONTELUKAST;

ACETATES; ADULT; ECCHYMOSIS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LOWER EXTREMITY; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 84883266264     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02298     Document Type: Article

References (25)

1. Masoli M, Fabian D, Holt S, Beasley R; on behalf of the Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469-478.
2. Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136(6):107-124.
3. Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics 2001;19(9):891-899.
4. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109(3):419-425.
5. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106(5):201-205.
6. Nayak A, Langdon R. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67(6):887-901.
7. Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag 2007;3(2):327-332.
8. Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad Med J 2000;76(902):767-773.
9. Jamali AN, Aqil M, Alam MS, Pillai KK, Kapur P. A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. J Pharm Bioallied Sci 2010;2(4):333-336.
10. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, et al; Montelukast/Beclomethasone Study Group. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999;130(6):487-495.
11. Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 2002;77(5):437-445.
12. Romero-Gómez M, Sánchez-Muñoz D, Castilla L, Castro M. [Acute hepatitis due to montelukast]. Med Clin (Barc) 2003;120(6):239. Article in Spanish.
13. Margery J, Dot JM, Bredin C, Bonnichon A, Romand F, Guigay J, et al. Montelukast induced cytolytic acute hepatitis. Gastroenterol Clin Biol 2003;27(1):129-130.
14. Sass DA, Chopra KB, Wu T. A case of montelukast-induced hepatotoxicity. Am J Gastroenterol 2003;98(3):704-705.
15. Litt JZ. Litt's drug eruption reference manual: including drug interactions, 11th edition. London: Informa; 2011:452.
16. UKMedicines and Healthcare Products Regulatory Agency and Committee on Safety of Medicines. Leukotriene receptor antagonists: update on adverse reaction profiles. Curr Probl Pharmacovigilance 1999;25:14.
17. DuMouchel W, Smith ET, Beasley R, Nelson H, Yang X, Fram D, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004;26(7): 1092-1104.
18. Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000;117(3):708-713.
19. Davis MD, Daoud MS, McEvoy MT, Su WP. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997;37(2):199-203.
20. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol 2000;114(5):767-772.
21. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279(6):455-457.
22. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000;55(9):805-806.
23. Masi AT, Hunder GG, Lie IT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33(8):1094-1100.
24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-245.
25. Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol 2007;26(10):1769-1771.